Takeda is divesting a portfolio of select non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm, a specialty Germany pharmaceutical company, for $562 million.
The portfolio is comprised of non-core prescription pharmaceutical products in a variety of therapeutic categories sold predominantly in Europe and Canada. This includes Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium. The portfolio generated FY 2019 net sales of approximately $260 million.
While the products included in the sale address key patient needs in these countries, they are outside of Takeda’s five key business areas. With a more focused portfolio, the divestiture further enables Takeda’s Europe & Canada Business Unit (EUCAN) to focus on and drive strategic core growth areas.
In April 2020, Takeda announced to divest EUCAN’s non-core over-the-counter (OTC) products to Orifarm Group.
“These divestments represent another important milestone in our portfolio simplification and optimisation strategy as we position Takeda for continued success across our five key business areas: Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience,” said Giles Platford, President of EUCAN.